Swedencare Ab · OMXSTO:SECARE
Swedencare Ab — Merger or Acquisition (January 2022)
14 slides from Swedencare Ab's merger presentation, January 2022
Slide 1: Acquisitions of NaturVet and Innovet
Acquisitions of NaturVet and Innovet January 2022 1
Slide 2: Disclaimer
Disclaimer This presentation (the "Presentation") has been prepared by Swedencare AB (publ) (the "Company") exclusively for information purposes and does not in itself constitute an offer, or a solicitation of an offer, to buy, subscribe for or otherwise acquire shares or other securities in the Com
Slide 3: Key terms and conditions
Key terms and conditions The Garmon Corporation doing business under the brand NaturVet (“NaturVet”) and Innovet Italia Srl (“Innovet” or jointly the “Targets” or the Targets “Acquisitions”) Acquisitions Swedencare AB (publ) (“Swedencare”) to acquire all shares outstanding of NaturVet and Innovet. T
Slide 4: Swedencare acquires US based NaturVet and Italian based Innovet
Swedencare acquires US based NaturVet and Italian based Innovet Scale and muscle Consolidating a niche market NaturVet LTM Sept’21 Sales of Transformative deals to speed SEK 548m with an adj. EBITDA up the process of becoming the of SEK 171m (31% adj. EBITDA market leader within pet margin) healthca
Slide 5: NaturVet at a glance
NaturVet at a glance A leading U.S. pet supplement manufacturer • Well diversified & high-end product portfolio o #1 pet supplement brand in four of the top five pet chains in U.S. Scott Garmon Management Team Established presence o 20 product categories include joint health, digestion, allergies an
Slide 6: Innovet at a glance
Innovet at a glance A leading Italian Vet Specialist • Leading vet specialist product company in Italy with an international ambition Renato della Valle Strong Highly efficient • Salesforce targeting vet clinics and pharmacies with 90% of sales Founder, CEO and main coming from Italy management and
Slide 7: Summary and synergies from the acquisitions
Summary and synergies from the acquisitions Growth opportunities and synergies – NaturVet Growth opportunities and synergies – Innovet • NaturVet´s international sales to be increased • Company’s international sales to be increased through Swedencare´s global distribution network through Swedencare´
Slide 8: Pole-position to become the market leader in Pet Healthcare
Pole-position to become the market leader in Pet Healthcare • Well diversified and innovative portfolio with premium products o Strong brands with high degree of customer loyalty o Products in most categories and in all distribution forms – powder, liquids, chews, soft chews and tablets • Strong pre
Slide 9: Proforma – LTM Sept'21
Proforma – LTM Sept’21 LTM Sept’21 Swedencare NaturVet Innovet Combined 1.7x SEK thousands Audited SEK thousands LTM Sept’21 LTM Sept’21 LTM Sept’21 1,611,285 LTM Sept’21 Group (SEK thousand) Total revenue 936,000 548,068 128,830 1,611,285 936,000 Gross profit 536,000 335,438 95,358 966,797 Gross ma
Slide 10: Illustration proforma captable
Illustration proforma captable Ilustration of proforma captable Current holding (pre PP and New Issues Of Consideration Shares) Post PP and New Issues Of Consideration Shares # Shareholders # of shares % # of shares % 1 Håkan Svanberg 23,007,275.00 19.47% 23,007,275.00 14.55% 2 Symrise AG 15,204,961
Slide 11: Risk factors (I/IV)
Risk factors (I/IV) Any investment in shares or other securities issued by Swedencare involves risk. A non-exhaustive overview of relevant risk factors that should be taken into account when considering an investment in Swedencare follows below. Risks related to Swedencare’s operations and industry
Slide 12: Risk factors (II/IV)
Risk factors (II/IV) Risks related to Swedencare’s operations and industry cont. It cannot be ruled out that several important customers reduce their purchases Swedencare’s customers are of different sizes and geographic locations and consist mainly of veterinary clinics, pharmacies and animal store
Slide 13: Risk factors (III/IV)
Risk factors (III/IV) Risks related to Swedencare’s operations and industry cont. Financing of the business might be expensive or difficult to obtain If the development of Swedencare’s business deviates materially from what has been projected, it may be necessary for Swedencare to increase the compa
Slide 14: Risk factors (IV/IV)
Risk factors (IV/IV) Risks related to Swedencare’s shares The share price can be volatile, and the share price development is affected by several factors An investment in shares is always associated with risk and risk-taking. Since a share price may fall in value, it is not certain that a shareholde